|
About
HealthPolCom
Consulting
 Dr.
Miller started HealthPolCom Consulting in 2000 after 12 years in health
policy positions in Washington, DC. He currently focuses on improving the
efficiency and accountability of health care deliver. His clients have included large and
small healthcare companies –
including Amgen, Endo, Johnson & Johnson, and
Pfizer –
as well as non-profit organizations, consulting, communications, and
venture capital firms. In October 2008, for his broad range of work to
improve the quality of health care,
he received an Rx
for Excellence Award from the Massachusetts Medical Law Report.
(Also see Case
Studies and Resume Summary)
 |
For
each project, Dr. Miller uses his knowledge and skills to develop
quantitative and qualitative information about the relevant health conditions and issues, and then synthesizes this information into
knowledge useful for each client’s internal customers and external
target audiences.
|
|
Dr.
Miller’s expertise in connecting with each stakeholder group, and
conveying important information to them, enables him to engage
individuals and groups, leading to improved relationships and outcomes.
|
|
Every
project and client has unique needs, and Dr. Miller manages each
engagement according to its individual requirements and goals.
The decades of experience that Dr. Miller and his network of associates
bring to every client ensures that project time and money are not wasted
“reinventing the wheel.”
|
Dr.
Miller's experience and consulting activities include:
|
A
consultant with expertise in the clinical, economic, scientific and
political arenas of healthcare, who solves healthcare business and policy problems.
|
|
A
seasoned advisor for solving complex advocacy, reimbursement strategy,
and stakeholder communications issues.
|
|
Working
with clients to develop and
execute integrated strategies to speed the development,
reimbursement and better use of new treatments and diagnostics.
|
|
Improving
the healthcare system for patients, companies and society by creating
stronger relationships, and better clinical and economic outcomes.
|
|
